RxDoctor Payments DataLook up a doctor →

Justin Winas, DO

Pain Medicine · Fort Washington, PANPI 1679789010

Payments from drug & device makers

$8,459in general payments, 2019–2025

Across 347 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$1K
  • Collegium Pharmaceutical, Inc.$854
  • Nevro Corp.$722
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$613
  • Vertos Medical, Inc.$529
  • plus $3K from 32 others

What the payments were for

  • Travel & lodging$3394%
  • Food & beverage$7,42096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,459 in reported general payments places this provider in the 80th percentile of 294 pain medicine providers in Pennsylvania.

See all pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$777,882
Medicare patients
477
Services billed
19,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PercocetOxycodone Hcl/Acetaminophen19$89,121
OxycontinOxycodone Hcl88$70,438
Nucynta ErTapentadol Hcl42$69,376
Xtampza ErOxycodone Myristate68$40,155
Buprenorphine98$24,756
Nurtec OdtRimegepant Sulfate13$24,372
Oxycodone Hcl839$21,542
Fentanyl83$15,874
Chlorzoxazone12$11,344
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen478$10,993
BelbucaBuprenorphine Hcl13$10,783
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen372$9,925
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl62$9,159
Emgality PenGalcanezumab-Gnlm12$7,812
Morphine Sulfate ErMorphine Sulfate230$6,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er, Belbuca$854$120,313123 claims
PfizerNurtec Odt$147$24,37213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 294 pain medicine providers in Pennsylvania.

Other pain medicine in Fort Washington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →